Vaccination strategies in patients with renal cell carcinoma
Vaccination strategies in patients with renal cell carcinoma
复制标题
DOI：
10.1007/s00262-009-0706-7
复制
发表时间：
2009-07-01
影响因子：
5.8
通讯作者：
Brossart, Peter
中科院分区：
文献类型：
--
作者：
Asemissen, Anne Marie;Brossart, Peter
尽管近年来针对晚期肾细胞癌（RCC）患者开发了新的治疗方案，但疫苗接种仍然是一种有前途的新兴治疗方案。目前，越来越多的可用于 RCC 的肿瘤相关抗原 (TAA) 已被使用并分析其对抗原特异性疫苗策略的功效。最近，在转移性肾细胞癌患者中使用树突状细胞进行抗原特异性疫苗接种被证明可以诱导与某些患者的客观临床反应相关的细胞毒性T细胞反应。此外，目前的研究重点是开发更有效的疫苗方案，例如应用多价、HLA 独立的 RNA 编码多种 TAA 和佐剂。初步结果证明了有希望的临床和免疫学功效。联合使用酪氨酸激酶抑制剂可能会提高抗原特异性疫苗接种的功效，因为在小鼠模型中，舒尼替尼被证明可以促进疫苗接种后 T 细胞的诱导并消除调节性 T 细胞。
Although new treatment options for patients with advanced renal cell cancer (RCC) have been developed within recent years, vaccination is still a promising emerging treatment option. An increasing number of tumor-associated antigens (TAA) available for RCC are currently used and analyzed for their efficacy for antigen-specific vaccine strategies. Recently, antigen-specific vaccination with dendritic cells in patients with metastatic RCC was shown to induce cytotoxic T cell response associated with objective clinical responses in some of the patients. Furthermore, current studies focus on the development of more effective vaccine regimes, such as the application of polyvalent, HLA-independent RNA coding for multiple TAA and adjuvants. First results demonstrate promising clinical and immunological efficacy. The efficacy of antigen-specific vaccination might be improved by a combination of tyrosine kinase inhibitors, since sunitinib was shown to promote T cell induction following vaccination in a mouse model and elimination of regulatory T cells.